COVID-19 vaccine: University of Oxford and AstraZeneca PLC have developed the first candidate vaccine to start the new coronavirus vaccine test circular
There is a massive avalanche among countries around the world to immunize their citizens who oppose the coronavirus. According to the World Health Organization, around 170 coronavirus vaccines are being developed worldwide lately. However, some of them are approaching the maximum level of testing.
Vaccines mimic the virus, or component of the virus, which they oppose, stimulating the immune formula to expand antibodies opposed to the disease.
HOW ARE VACUNAS TESTED?
Coronavirus vaccine: pioneers:
University of Oxford / AstraZeneca: The University of Oxford and AstraZeneca PLC have developed the first candidate vaccine to start the newest circular of coronavirus vaccine tests The Indian Serum Institute (IIF) has signed an agreement with AstraZeneca to manufacture a COVID-19 vaccine candidate for India and low- and middle-income countries.The Internal Revenue Service (IRS) has decided at 17 sites in India to conduct the phase 2 trial of the Oxford COVID-19 vaccine.
In addition, phase trials of the Oxford vaccine are being conducted in the United States, the United Kingdom, Brazil and South Africa.
AstraZeneca is aiming for 2 billion international doses and said 1 billion doses of the vaccine will come this year.
2.Modern Vaccine: The US biotechnology company Modern presents a vaccine messenger RNA (or mRNA, in short) candidate to induce the framework to produce viral proteins by itself. And the U.S. National Institute of Allergy and Infectious Diseases.But it’s not the first time They are testing two doses The Candidate of Moderna was the first to participate in human trials in the United States.The tests for the final phase of Moderna are underway with 30,000 human trials that can produce provisional effects until the end of 2020.The mNR vaccine has never been approved for any disease.Moderna has promised to supply between 500 million and one billion doses according to the year from 2021.
Pfizer: US biotechnology company Pfizer is also presenting a vaccine against The Coronavirus Mr. A.Pfizer and his German wife BioNTech SE have begun recruiting another 30,000 people at 120 other sites.The U.S. government approved $2 billion in bills for Pfizer and BioNTech for one hundred million doses Pfizer is estimated to distribute 1.3 billion doses by the end of 2021.
4.Sinopharm: Chinese biotechnology company Sinopharm will present two coronavirus vaccines with the Wuhan Institute of Biological Products and the Beijing Institute of Biological Products.
Currently, Sinopharma has reached an agreement to conduct tests in several countries, adding Pakistan and the United Arab Emirates.Chinese officials said they need to make a vaccine to have the public before the end of the year with a production capacity of 220 million.dose according to the year.
5.Sinovac: This is a chinese personal company that started the last test in Brazil in July.Sinovac also signed an agreement with an Indonesian pharmaceutical company called PT Bio Farm to manufacture up to 250 million doses of vaccines a year for Indonesians.
6th Johnson
Johnson
Novavax Inc: Novavax, in the United States, manufactures a vaccine consisting of two injections given 21 days apart.The vaccine releases proteins that resemble the tip of SARS-CoV-2.Researchers expect the protein to cause the production of antibodies and immune cells capable of fighting coronavirus.Novavax plans to supply one hundred million doses for use in the United States.
8.Gamaleya Research Institute: The Gamaleya Research Institute in Russia is preparing an anti-coronavirus vaccine in the mixture of two adenoviruses. Although Russia had already approved the use of the vaccine in early August, the vaccine had not undergone any final stage testing.The Russian government is planning a mass vaccination in October.
Read also: The AstraZeneca coronavirus vaccine goes into testing in the US.But it’s not the first time
Read also: Coronavirus Update: India reports 69,921 in 24 hours; workload approaches 37 lakh
Speak now